A new study published in Nature Communications by researchers at the Leibniz Institute for Natural Product Research and Infection Biology (Leibniz-HKI) and their collaborators in Hungary and Denmark sheds light on the human gut microbiome. The study examined stool samples from 75 cancer patients, finding that certain bacterial species always appear in greater numbers when the amount of fungi from the Candida genus is high. 

Search Antibodies
Search Now Use our Antibody Search Tool to find the right antibody for your research. Filter
by Type, Application, Reactivity, Host, Clonality, Conjugate/Tag, and Isotype.

The researchers developed a computer model to predict the amount of Candida albicans in another group of patients with an accuracy of about 80% based on bacterial species and amounts alone.

The bacteria included mainly oxygen-tolerant species, which surprised the researchers. The researchers found an increased number of bacterial species that produce lactic acid, including Lactobacillus species. Several studies have attested to the protective effect of lactic acid bacteria against fungal infections. The researchers' hunch is that lactic acid bacteria, particularly of the genus Lactobacillus, favor C. albicans proliferation while making the fungus less virulent. This could be because Candida species can switch their metabolism to be able to use the lactate produced by lactic acid bacteria.

The researchers found that this gives C. albicans a competitive advantage over other fungi, such as Saccharomyces cerevisiae, as later discovered in additional experiments from the team. However, the metabolic switch also apparently causes Candida to remain in its usually harmless spherical yeast form instead of forming fungal hyphae that could invade the intestinal mucosa.

"There is also a suggestion that certain groups of Lactobacillus species might have different effects," says lead author Bastian Seelbinder. To investigate this further, next steps include performing more detailed genomic analyses of the bacteria. For further studies, samples from healthy subjects could be included in these analyses to develop long-term strategies for at-risk patients based on their microbiomes.